• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Scorpius Holdings Inc.

    4/28/25 8:00:02 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPX alert in real time by email
    RW 1 scpx_rw.htm REGISTRATION WITHDRAWAL RW

    A logo of a dinosaur

Description automatically generated

     

     

    April 28, 2025

     

    VIA EDGAR

     

    United States Securities

    and Exchange Commission

    Division of Corporation Finance

    100 F Street, N.E.

    Washington, D.C. 20549

     

     

      Re: Scorpius Holdings, Inc. f/k/a
    Nighthawk Biosciences, Inc.
     
        Registration Statement on Form S-3  
       

    Filed December 19, 2023

    File No: 333-276144

     

     

    Dear Sir or Madam:

     

    Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Scorpius Holdings, Inc. f/k/a Nighthawk Biosciences, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Registrant’s Registration Statement on Form S-3, File No. 333-276144, together with all amendments and exhibits thereto (the “Registration Statement”). The Registrant does not intend to conduct the offering of the shares of common stock contemplated by the Registration Statement due to changed circumstances since the filing of the Registration Statement. No shares of common stock of the Registrant have been or will be issued or sold under the Registration Statement.

     

    Accordingly, the Registrant requests an order granting the withdrawal of the Registration Statement to be issued by the Commission as soon as possible.

     

    The Registrant acknowledges that no refund will be made for fees paid to the Commission in connection with filing of the Registration Statement. However, the Registrant requests, in accordance with Rule 457(p) under the Securities Act that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Registrant’s account to be offset against the filing fee for any future registration statement or registration statements.

     

    Please contact Leslie Marlow at (212) 885-5358 or Melissa Palat Murawsky at (215) 569-5732 with any questions you may have concerning this application of withdrawal of the Registration Statement, and please notify either Ms. Marlow or Ms. Murawsky when this application of withdrawal has been granted.

     

      Very truly yours,
         
      SCORPIUS HOLDINGS, INC.
         
      By: /s/ Jeffrey Wolf
        Name:  Jeffrey Wolf
        Title: Chief Executive Officer

     

    cc:   Leslie Marlow, Blank Rome LLP 

    Melissa Palat Murawsky, Blank Rome LLP

     

    Get the next $SCPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCPX
    SEC Filings

    See more
    • Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

      6/3/25 4:30:27 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

      5/20/25 5:07:29 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Scorpius Holdings Inc.

      NT 10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)

      5/15/25 5:24:59 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

      Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and tec

      5/14/25 8:30:00 AM ET
      $SCPX
      $TIVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

      Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

      5/5/25 8:00:00 AM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining

      SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the year ended December 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO capabilities. While the delay in our Form 10-K filing was not id

      4/30/25 4:05:30 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Scorpius Holdings Inc.

      SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

      9/26/24 4:05:52 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Scorpius Holdings Inc.

      SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

      9/6/24 4:01:41 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Scorpius Holdings Inc. (Amendment)

      SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)

      5/21/24 5:25:39 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Thuan Tan Sze

      3 - Scorpius Holdings, Inc. (0001476963) (Issuer)

      3/12/25 4:07:02 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolf Jeffrey Alan was granted 2,500,000 shares (SEC Form 4)

      4 - Scorpius Holdings, Inc. (0001476963) (Issuer)

      5/17/24 4:30:21 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

      Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

      5/5/25 8:00:00 AM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

      DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand fo

      11/14/24 4:15:00 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats

      DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu

      10/2/24 8:00:00 AM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care